Replies to post #105 on PTC Therapeutics Inc (PTCT)

[chainma1l]

SRPT was a strong buy last week when Farkas left. I was able to add 1,000 shares to my holdings and that worked out very well.
PTCT is the speculative play now. Already has approval in England and a renewal in Europe is pending. Company already has $60+ million in sales per year. They don't treat the same form of DMD that Sarepta does, so with Farkas gone, that is a VERY good sign. Hopefully the FDA comes through for PTC as well. If it does, the pps should see appreciation similar to SRPT.